Kornimate/medical-research-clean huggingface dataset:
provider notification for high b-type natriuretic peptide values

Conditions: Heart Failure

Summary: this proposal examines use of a clinical reminder to the primary provider of patient with a high b type natriuretic peptide but no prior imaging. electrical medical record-based intervention to determine whether clinical reminders improve heart failure management in patients with high bnp values and unknown lvef.

rationale: b type natriuretic peptide is known to be elevated (\> 100 pg/ml) in patients with heart failure. furthermore, treatments are available to improve survival and reduce hospitalization if the left ventricular ejection fraction (lvef) is \< 40%. accordingly, guidelines recommend an lvef measure for patients with suspected heart failure. prior work has demonstrated that patients with high bnp values do not always have a measure of left ventricular ejection. hypothesis: a reminder to patients with bnp and no imaging may prompt providers to order appropriate imaging potentially leading to 1) identification of unsuspected depressed ejection fraction and 2) more appropriate treatment.

Eligibility criteria:
inclusion criteria: * bnp \>= 200 pg/ml in last 2 months exclusion criteria: * measure of lvef in the last 12 months * last measure of lvef \< 40%

Keywords: b type natriuretic peptide heart failure cardiac imaging quality of care
gender-related differences in chinese patients with aad

Conditions: Aneurysm Dissecting

Summary: few data exist on gender-related differences in clinical features, management, and outcomes of acute aortic dissection (aad) in china. accordingly, we enrolled 2015 patients with aad from 15 hospitals in china to access differences in clinical features, management and outcomes between men and women. in this study, our results provided new insights into gender-related differences in clinical features, management and outcomes in the chinese patients with aad. important implications may be helpful to improve diagnostic and therapeutic outcomes.


Eligibility criteria:
inclusion criteria: * patients with acute aortic dissection exclusion criteria: * simple dilated aneurysm and penetrating atherosclerotic ulcer

Keywords: aortic dissection chinese patients gender differences
monitoring sleep, wellbeing, and glucose metabolism in pgy1s

Conditions: Sleep; Glucose Metabolism Disorders

Summary: overnight on-call schedules can impact sleep, wellbeing, and alertness, which can be detrimental on the performance, physical and mental health of residents. moreover, rotating shift work may have a long-term negative health impact (e.g. increased risk of diabetes). within the national university hospital (nuh), two different systems of rotating on-call schedules are implemented. in the night float system, residents work from 8 pm to 8 am for 5 - 7 consecutive nights once every month, compared to the traditional overnight on-call system, where each resident is on call for 4-6 nights per month (7 am - 5 pm, followed by overnight call until 8 am the next morning). the aim of the current study is to track sleep, wellbeing, and glucose metabolism during the different phases of the night float and traditional on-call schedules.

overnight on-call schedules can impact sleep, wellbeing, and alertness, which can be detrimental on the performance, physical and mental health of residents. moreover, rotating shift work may have a long-term negative health impact (e.g. increased risk of diabetes). within the national university hospital (nuh), two different systems of rotating on-call schedules are implemented. in the night float system, residents work from 8 pm to 8 am for 5 - 7 consecutive nights once every month, compared to the traditional overnight on-call system, where each resident is on call for 4-6 nights per month (7 am - 5 pm, followed by overnight call until 8 am the next morning). the aim of the current study is to track sleep, wellbeing, and glucose metabolism during the different phases of the night float and traditional on-call schedules. the availability of accurate mobile methodologies to monitor sleep and metabolic health provide new avenues for the improvement of sleep health and well-being. wearable sleep tracking devices and smartphone apps provide remarkable opportunities for non-invasive, longitudinal sleep detection. measurement of sleep during different stages of the shift schedule (baseline, on-call, recovery) can provide detailed insights into the temporal impact of the different schedules. moreover, self-reported ratings of sleep quality, wellbeing, and time-use (delivered through phone-based e-diary methods) can further detail the mental health impact associated with these schedules. wearable continuous glucose monitoring systems (cgms) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.

Eligibility criteria:
inclusion criteria: * nuhs postgraduate year 1 doctors * above 21 years of age * completing their year 1 rotations in 2021 or 2022 exclusion criteria: * as this is an observational study with minimal risk, in an restricted pool of participants, no further exclusion criteria will be applied for participation.
influence of hematocrit level on the visibility of the venous network in magnetic susceptibility imaging

Conditions: Stroke

Summary: magnetic susceptibility imaging is a magnetic resonance imaging (mri) technique that uses the magnetic properties of tissues and the bold (blood oxygen level-dependent) effect. it allows a better visualization of venous structures and hemorrhagic lesions. these sequences are now used in clinical routine. the extreme sensitivity of these sequences to the oxy/deoxyhemoglobin ratio makes it possible to describe a new mri semiology, particularly in the context of cerebral ischemia. the interest of the analysis of the venous network signal, which can reflect cerebral perfusion, has been reported. however, the influence of the hematocrit level on the signal of the venous network in magnetic susceptibility imaging has not been evaluated at present. it seems important to better define the influence of hematocrit level on the signal of the veins with this sequence to avoid potential diagnostic errors.


Eligibility criteria:
inclusion criteria: * patient whose age ≥ 18 years * patient referred to ghpsj for suspected stroke * patient who had a brain mri including the magnetic susceptibility sequence * patient for whom a blood count with hematocrit was performed at the same time (within 7 days between the mri and the blood test) * french-speaking patient exclusion criteria: * patient under guardianship or curatorship * patient deprived of liberty * patient under court protection * elimination of potential biases: recent injection (48 h) of gadolinium, pathology likely to modify the venous signal in magnetic susceptibility imaging (notably arterial occlusion or stenosis), high flow oxygenation, sickle cell disease, thalassemia. * patient objecting to the use of his/her data for this research
intelligent-c endoscopy module for real-time detection of colonic lesions

Conditions: Artificial Intelligence; Colonic Polyp

Summary: to conduct an single blinded, non-randomized, prospective, single center trial to validate the performance of a novel state-of-the-art artificial intelligence model (ai-model) for colorectal lesion detection during routine diagnostic colonoscopy and to evaluate its feasibility in daily endoscopy. consecutive patients referred for a screening, surveillance or diagnostic colonoscopy will be included

all procedures will be performed with high-definition endoscopes; bowel preparation will be conducted according to usual local practices. during colonoscopy, the colonoscope will be first advanced to the cecum in all patients as confirmed by identification of the appendicular orifice and ileocecal valve or by intubation of the ileum, as per the standard of care by experienced endoscopists. during the insertion, no action will be taken. after cecal intubation is performed, the colonoscope will be slowly withdrawn to the splenic flexure by the primary endoscopists. real time ai detection model will be activated with the output displayed in real time on a separate monitor and will be only viewed by an independent investigator, who is an experienced endoscopists (or a person trained in polyp recognition). the primary endoscopists will be blinded to the ai real time detection result all detected polyps will be removed or with biopsy taken during this examination and sent for histopathology examination.

Eligibility criteria:
inclusion criteria: 1. patients undergoing colonoscopy of age 18 to 80 years. 2. patient who has read the informed consent form, has understood the relevant aspects of the study, and grants his/her authorization to participate by signing the informed consent form before the inclusion in the study and the performance of any procedure 3. consecutive adult patients scheduled to undergo routine colonoscopy at aig exclusion criteria: 1. females who are pregnant 2. patients who are unsuitable for any other reason to participate in the study in the opinion of the investigator 3. recent colonoscopy within past 12 month 4. history of inflammatory bowel disease 5. history of colorectal cancer 6. previous bowel resection (apart from appendectomy) 7. peutz-jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes 8. bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe.
mobile continuing care approach for youth

Conditions: Addiction

Summary: the primary purpose of this study is to test the effectiveness of a pilot mobile based continuing care program (monitoring/feedback texting) relative to standard continuing care as usual in reducing relapse and improving psychosocial functioning outcomes in a youth population (under 24) with substance abuse problems.

this study will include approximately 80 participants randomized to either 12 weeks of mobile continuing care (intervention) or standard continuing care as usual (control). participants will be recruited from the treatment programs in los angeles county, including matrix institute on addictions, tarzana treatment, twin town, phoenix house, and cri-help. during the 12-week active program, participants will be monitored monthly via telephone data collection. both groups will be followed for 10-months using repeated assessments (self-report and urine specimens) at baseline (month 0) and at follow-up points (months 3, 6, and 9).

Eligibility criteria:
inclusion criteria: 1. youth between 12 and 24 years old 2. youth in treatment for substance abuse 3. youth who complete treatment (minimum 12 weeks) 4. youth who have the cognitive capacity to understand study procedures and agree to participate exclusion criteria: 1. presence of an adverse (life threatening) medical condition that could interfere with study participation. 2. presence of psychiatric co-occurring illness or symptoms warranting safety concerns or continued treatment, including acute suicide risk; and 3. current homelessness (unless residing in recovery home for which contact information can be provided).

Keywords: continuing care youth substance abuse recovery support mobile texting
association between local cerebral oxygenation monitoring and postoperative delirium in carotid endarterectomy

Conditions: Cerebral Oxygen Saturation; Postoperative Delirium; Carotid Endarterectomy

Summary: postoperative delirium (pod) is a common perioperative complication, which can lead to adverse outcomes. patients undergoing carotid endarterectomy (cea) were elderly, complicated with vascular risk factors, cognitive dysfunction, some also had a history of stroke, and the circulation fluctuated greatly during the operation, often resulting in hypoperfusion of cerebral tissue and hypoxia. therefore, they're the high-risk group of pod. near-infrared spectroscopy (nirs) can continuously and noninvasively monitor local cerebral oxygen saturation (scto2) to identify the mismatch of oxygen supply and demand in brain tissue. however, for cea patients, the association between intraoperative scto2 changes and pod remains unclear. this study intends to explore the association between them and determine the scto2 threshold for predicting pod. we will monitor scto2 intraoperatively, follow up and collect data postoperatively.


Eligibility criteria:
inclusion criteria: scheduled carotid endarterectomy; signed informed consent. exclusion criteria: severe cognitive impairment(mini-mental state examination, mmse\<18); history of psychotropic drugs; previous intracranial surgery history; poor hearing or vision; language barriers
spontaneous evisceration of infantile umbilical hernia

Conditions: Pediatric Disorder

Summary: infantile umbilical hernia is common in children. it has a regressive course in most cases. conservative management is the standard in most cases before the age of 3 years unless there are complications such as incarceration, rupture with evisceration which are extremely rare and warrants emergency surgery. we present a rare case of a 6-month-old child with sudden spontaneous evisceration of infantile umbilical hernia.

infantile umbilical hernia is common in children. it has a regressive course in most cases. conservative management is the standard in most cases before the age of 3 years unless there are complications such as incarceration, rupture with evisceration which are extremely rare and warrants emergency surgery. we present a rare case of a 6-month-old child with sudden spontaneous evisceration of infantile umbilical hernia.

Eligibility criteria:
inclusion criteria: * pediatric group exclusion criteria: * adult group
safety and efficacy of voxilaprevir plus sofosbuvir/velpatasvir fixed dose combination in adults with chronic genotype 1 hcv infection

Conditions: Hepatitis C Virus Infection

Summary: this primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (vox) plus sofosbuvir/velpatasvir (sof/vel) fixed dose combination (fdc) ± ribavirin (rbv) in adults with chronic genotype 1 hepatitis c virus (hcv) infection.


Eligibility criteria:
key inclusion criteria: * individuals with chronic hcv infection * hcv rna ≥10\^4 iu/ml at screening * hcv genotype 1 * cirrhosis determination; a liver biopsy may be required * screening laboratory values within defined thresholds * use of two contraception methods if female of childbearing potential or sexually active male key exclusion criteria: * pregnant or nursing female * current or prior history of hepatic decompensation * hepatocellular carcinoma (hcc) or other clinically significant malignancy * infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv) * history of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol note: other protocol defined inclusion/exclusion criteria may apply.
specified drug use-results survey of betanis tablets for patients with coexisting cardiovascular disease

Conditions: Overactive Bladder; Cardiovascular Disease

Summary: this purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.


Eligibility criteria:
inclusion criteria: * having coexisting cardiovascular disease or a history of cardiovascular diseases * having electrocardiogram record conducted within seven days before the start of the mirabegron treatment (including the first day of administration) exclusion criteria: * having serious cardiovascular disease * having significant long qt (qtc \> 500 msec)

Keywords: mirabegron overactive bladder cardiovascular disease
applying an artificial intelligence-enabled electrocardiographic system for reducing mortality

Conditions: Cardiovascular Diseases; Intensity Care; Morality

Summary: this is a randomized controlled trial (rct) to test a novel artificial intelligence (ai)-enabled electrocardiogram (ecg)-based screening tool for early detection of clinical deterioration for reducing mortality.


Eligibility criteria:
inclusion criteria: * patients in emergency department or inpatient department. * patients recieved at least 1 ecg examination. exclusion criteria: * the patients recieved ecg at the period of inactive ai-ecg system.
a study of mircera in anemic patients with non-small cell lung cancer receiving first line chemotherapy.

Conditions: Anemia

Summary: this 4 arm study will assess the optimal starting dose of mircera in the treatment of anemia in patients with non-small cell lung cancer receiving first line myelosuppressive chemotherapy. patients will be randomized to receive either mircera 6.3 micrograms/kg, 9 micrograms/kg or 12 micrograms/kg s.c. every 3 weeks or darbepoetin alfa according to the approved local label (either 6.75 micrograms/kg s.c. every 3 weeks, or 2.25 micrograms/kg every week). the anticipated time on study treatment is \<3 months and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * \>=18 years of age; * stage iii or iv non-small cell lung cancer receiving first line myelosuppressive chemotherapy; * myelosuppressive chemotherapy scheduled for at least 9 weeks; * anemia at screening visit. exclusion criteria: * transfusion of red blood cells during the 4 weeks prior to first planned dose of study medication; * iron deficiency anemia, or anemia caused by gastrointestinal bleeding; * prior treatment with mircera.
effect of a resilience model-based care plan in newly diagnosed colorectal cancer patients

Conditions: Colon Cancer

Summary: the aims of this three-year study are to explore the protective and risk factors of resilience in colorectal cancer patients, and examine the effect of the resilience model-based care plan in reducing fear of recurrence and gi symptom distress and improving quality of life in newly diagnosed colorectal cancer (crc) patients.

develop and evaluate the effect of a resilience model-based total care plan on reducing fear of recurrence and gi symptom distress and improving quality of life (qol) in this population.

Eligibility criteria:
inclusion criteria: * patients with stage i to iii colon cancer. exclusion criteria: * patients with cancer other than colon cancer or have cancer recurrence.

Keywords: fatigue colon cancer quality of life
study on long term outcomes of atazanavir in antiretroviral-naïve human immunodeficiency virus (hiv) patients in real life setting

Conditions: HIV

Summary: the purpose of this study is to describe long term (\> 96 weeks) efficacy and safety of atazanavir-based regimens in real life setting.

time perspective: collection of historical data and longitudinal follow up. patients will be enrolled in 2011/2012 but data will be collected from medical charts from atv initiation date (feb 2008 - july 2010) until july 2013 at the latest (if no atv discontinuation, or death, or lost to follow up). non probability sample: * specialized hiv management centers will be contacted in order to recruit about 15-20 sites per country. * each site will have to enroll an average of 8-12 consecutive patients (min:5; max:30) fulfilling the inclusion/exclusion criteria.

Eligibility criteria:
inclusion criteria: * male or female hiv patients ≥ 18 years old at atv/rtv initiation treatment date * outpatient seen in routine consultation whatever the reason, between january 1st 2011 and march 31st 2012 * commencing an atv/rtv-based regimen including at least 2 nucleoside reverse transcriptase inhibitors (nrti) after february 1st 2008 and before july 31st 2010, regardless of the current arv treatment ongoing at enrollment visit exclusion criteria: * patient exposed to or who began atv/rtv prior to february 1st 2008, or after july 31st 2010 or without a known start date for atv/rtv therapy * exposure to more than 4 weeks of any arv prior to initiation of atv/rtv treatment * participation in a clinical trial with atv at the time of or after initiation of atv/rtv-based regimen
safety and efficacy study of microplasmin in for non-surgical treatment of focal vitreomacular adhesion

Conditions: Focal Vitreomacular Adhesion

Summary: this study will evaluate the safety and efficacy of microplasmin administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. ultimately, it is believed that intravitreal microplasmin may offer physicians a safe agent for pharmacologic vitreolysis and induction of posterior vitreous detachment (pvd) without the need for vitrectomy. this clinical study is justified because the study sponsor believes the potential benefits outweigh the potential risks, as outlined below.


Eligibility criteria:
inclusion criteria: * i. male or female patients aged \> 18 * ii. presence of focal vitreomacular adhesion (ie, central vitreal adhesion within 6mm oct field surrounded by elevation of the posterior vitreous cortex * iii. bcva of 20/32 or worse in the study eye * iv. bcva of 20/400 or better in the contralateral eye * v. written informed consent obtained from the patient prior to inclusion in the study exclusion criteria: * i. evidence of complete macular pvd in the study eye on biomicroscopy, b-scan or oct prior to planned study drug injection * ii. any evidence of proliferative retinopathy meeting the definition for pdr in the study eye * iii. patients with vitreous hemorrhage which precludes either of the following: visualization of the posterior pole by visual inspection or adequate assessment of the macula by either oct and/or fluorescein angiogram in the study eye * iv. patients with rhegmatogenous retinal detachment, pvr, or retinal degenerative changes associated with increased risk of retinal detachment in the study eye. such retinal degenerative changes include lattice degeneration or cystic retinal tufts. thorough retinal examination should be performed in all patients to rule out these changes. * v. patients with high myopia (\> 8d) or aphakia in the study eye vi. patients with history of rhegmatogenous retinal detachment in the fellow eye vii. patients who have had ocular surgery in the study eye in the prior three months viii. patients who have had a vitrectomy in the study eye at any time. ix. patients with glaucoma that is not controlled with topical medication or that is associated with severe visual field loss, documented by perimetry, in the study eye x. patients who have had laser photocoagulation treatment in the study eye in the previous 3 months xi. intravitreal injection of any drug in the study eye in the previous 3 months xii. patients who are pregnant or of child-bearing potential not utilizing a form of contraception acceptable to the investigator xiii. patients who, in the investigators view, will not complete all visits and investigations, including the last visit at 6 months after the last injection xiv. patients who have participated in an investigational drug study within the past 30 days xv. patients with hypertension (either sbp \> 170 or dbp \> 100 mm hg) xvi. patients with a life expectancy less than 6 months xvii. patients who have previously participated in this trial